Cardiome Pharma Corporation is the product focused cardiovascular drug developing enterprise with twin clinical drug programs focused on arterial arrhythmia – intravenous and oral dosing as well as the pre-clinical program intended for increasing cardiovascular activities.

The intravenous formulation of Vernakalant is the new untried drug which is under assessment for the sharp adaptation of arterial fibrillation – AF. Positive top-line conclusions from the two essential phase 3 trials for Vernakalant known as ACT 1 and ACT 3 were released during December 2004 and September 2005 respectively. However, the extra phase 3 studies for assessing the patients with post-surgery arterial arrhythmia termed as ACT 2, as well as the open label safety study assessing new incepted AF patients termed as ACT 4, is continuing. Astella Pharma Inc., the co-development partner for Vernakalant has tendered the NDA – New Drug Application for Vernakalant sometimes during December 2006.       

Vernakalant – oral form is also under study and analysis as the persistent use oral drug for the maintenance of regular heart beats after termination of AF – arterial fibrillation. Cardiome has declared the positive outcomes from the phase 2a direct study for Vernakalant. Vernakalant oral medication is believed to avert or inhibit the reversal of arterial fibrillation – AF as well as it is indicated for use as the resultant therapy to Vernakalant.

Vernakalant poses to be unsuccessful of adapting arterial flutter patients to regular heart beat rates. Only 1 out of 39 patients were administered RSD 1235 dose transformed to regular heart beat rates, whereas not even a single patient out of 15 patients who were on placebo transformed to regular heart beat rates.